EUCTR2009-009517-18-IT
Active, not recruiting
Not Applicable
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study theSafety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - ND
DrugsGLUCOPHAGE
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- MERCK & CO., INC.
- Enrollment
- 335
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All laboratory measurements are to be performed after an overnight fast \&\#8805;12 hours in
- •duration. Patients with laboratory screening values/findings not meeting protocol
- •inclusion criteria may, at the discretion of the investigator, have a single repeat
- •determination performed. If the repeat value satisfies the criterion, they may continue in
- •the screening process. Only the laboratory test(s) not meeting inclusion criteria should be
- •repeated (not the entire panel).
- •Patients must meet all of the following inclusion criteria to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •All laboratory measurements are to be performed after an overnight fast \&\#8805;\&\#61472;12 hours in
- •duration. Patients with screening values outside the ranges described in the protocol
- •may, at the discretion of the investigator, have one repeat value determination performed
- •and if the repeat value does not meet the exclusion criterion they may continue the
- •screening process. Only the specific out\-of\-range value/finding should be repeated (not
- •the entire panel).
- •Individuals are excluded from participation in the study if they meet any of the following
- •exclusion criteria.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlCTRI/2009/091/000614Merck Co Inc276
Active, not recruiting
Phase 1
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - A Study of the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus.Type 2 Diabetes MellitusMedDRA version: 9.1 Level: LLT Classification code 10012601 Term: Diabetes mellitusEUCTR2009-009517-18-GRMerck & co.Inc333
Active, not recruiting
Not Applicable
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled,Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients withType 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - A Study of the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus.Type 2 Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2009-009517-18-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.333
Completed
Not Applicable
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlPER-019-09MERCK SHARP & DOHME PERU S.R.L.,
Active, not recruiting
Not Applicable
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled,Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients withType 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - A Study of the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus.EUCTR2009-009517-18-HUMerck and Co. Inc.241